信达生物IL-23p19单抗3期临床研究完成首例受试者给药,针对银屑病

动脉网
31 May

信达生物完成IL-23p19单抗3期临床研究首例给药,针对银屑病。该研究旨在评价匹康奇拜单抗对IL-17单抗应答不佳患者的疗效和安全性。此前2期研究显示,匹康奇拜单抗对生物制剂治疗无应答患者有效。IBI112通过阻断IL-23受体介导信号通路发挥抗炎作用,有望提供更有效、更长给药周期的治疗方案。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10